Assessment of immunological indicators in children with behavioral disorders due to perinatal cerebrovascular lesions

Abstract

Purpose - a comprehensive study of the immune system of patients with deviant behavior due to perinatal pathology.

Materials and methods. The sample consisted of 43 boys aged 7 to 15 years with a history of perinatal hemorrhagic and hypoxic-ischemic cerebrovascular injuries, which later provoked various forms of non-psychotic deviant behavior. To check the results, a control group consisting of 43 mentally and physically healthy children and adolescents was selected. The main group, which showed persistent deviant behavior, was prescribed a drug whose active substance is dalargin, a peptide compound whose structure includes 6 amino acid residues.

Clinical-amnestic, clinical-psychopathological, neurosonography was used to diagnose perinatal cerebrovascular injuries in newborns (in history) with subsequent use of computed tomography (CT) and magnetic resonance imaging (MRI) methods, statistical data processing was carried out using «SPSS 16.0» and «Excel» programs from the «Microsoft Office 2003» package.

Results. The study of T- and so-called T-active lymphocytes of the peripheral blood showed that before treatment, a significant decrease in the content of these cells was observed in children (to 4.26±0.80% and 22.42±0.69% against 65.81±1.66% 44.42±1.25% in the control group, p>0.05). Proliferative activity changes significantly in response to T- and B-mitogens. Proliferative activity recovered completely (25.56±3.26% and 59.72±2.19% vs. 57.23±1.51% in the control group).

Conclusions. Children and adolescents with pronounced deviant behavior of residual organic genesis, resistant to traditional therapy, are characterized by significant changes in the immune status caused by dysimmunoglobulinemia, imbalance of the lymphocyte subpopulation, suppression of the functional activity of these populations on mitogens, which indicates secondary immunodeficiency. The therapeutic effectiveness of the dalargin-peptide compound is determined by its function as an immunocorrector in treatment-resistant behavioral disorders.

The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of participating institution. The informed consent of the patient was obtained for conducting the studies.

No conflict of interests was declared by the authors.